Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Evolent Health, Inc. reported the quarter ended March 31, 2023 results: revenue $427.7 million, net income Net loss attributable to common shareholders of Evolent Health, Inc. of $26.3 million.
- Period
- the quarter ended March 31, 2023
- Revenue
- $427.7 million
- Net income
- Net loss attributable to common shareholders of Evolent Health, Inc. of $26.3 million
- Result
- reported results
Exact text from the filing
to payers and providers, today announced financial results for the quarter ended March 31, 2023. Highlights from the first quarter 2023 announcement include: • Revenue of $427.7 million, an increase of $130.6 million, or 44.0%, from the three months ended March 31, 2022. • Net loss attributable to common shareholders of Evolent Health, Inc. of $26.3 million
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Steve Tutewohl departed as Chief Operating Officer at Evolent Health, Inc..
- Action
- departure
- Role
- Chief Operating Officer
Exact text from the filing
In connection with organizational restructuring, the Company is announcing the departure of Steve Tutewohl, Chief Operating Officer.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Emily Rafferty was appointed as Chief Operating Officer at Evolent Health, Inc..
- Action
- appointed
- Role
- Chief Operating Officer
Exact text from the filing
On May 3, 2023, the Company’s Board of Directors appointed Emily Rafferty to serve as the Company’s Chief Operating Officer, effective July 3, 2023.
View on SEC.gov